IL17A and prostate cancer: The KEGG pathway enrichment analysis showed that the active target genes of ZRYZD acting on UC were significantly enriched in lipid and atherosclerosis, receptor for advanced glycation end products (AGE)-receptor for AGE (RAGE) signaling pathway in diabetic complications, fluid shear stress and atherosclerosis, hepatitis B, prostate cancer, chemical carcinogenesis-receptor activation, pancreatic cancer, bladder cancer, IL-17 signaling pathway, hepatitis C, and other pathways (Supplementary File 5).